- Company
- The third challenge of Imbruvica's primary therapy
- by Eo, Yun-Ho Jun 22, 2022 05:59am
- BTK inhibitor Imbruvica will take on its third challenge to expand insurance benefits. According to related industries, the first-line therapy indication of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in Imbruvica will be presented again to the HIRA Cancer Disease Review Committee on the 29th. Imbruvica's first-l
- Policy
- Alecensa's price cut 4.5%, Remodulin 4% due to excess sales
- by Kim, Jung-Ju Jun 22, 2022 05:59am
- Roche Korea’s non-small cell lung cancer treatment Alecensa 150mg Cap. (alectinib hydrochloride) became subject to negotiations under the Price-Volume Agreement (PVA) and will be supplied at a 4.5% discounted price starting next month. Price of Remodulin Inj. (treprostinil) that is used to treat patients with pulmonary arterial hypertension wil
- Company
- K-botulinum products are expanding globally
- by Jun 22, 2022 05:59am
- Domestic botulinum toxin is entering various parts of the world. Feeling limited in the domestic market, developers are targeting the U.S., Europe, and China, which are the largest markets in the world, while expanding their scope to countries such as Australia and the Middle East. ◆ Hugel is targeting Europe and North America, and Chi
- Policy
- The benefit discussion for Steglatro was excluded
- by Lee, Tak-Sun Jun 22, 2022 05:58am
- While the HIRA is discussing the standard for combination therapy benefits for SGLT-2-suppressing diabetes treatments, only Steglatro (MSD Korea) has been excluded from the combination of TZD affiliates, drawing attention. While the combination of DPP-4 inhibitors between families is recognized, the combination between TZD families is differenti
- Policy
- Report of severe skin SE such as rash of Phenytoin
- by Lee, Hye-Kyung Jun 21, 2022 05:55am
- Precautions for severe skin abnormalities will be newly established in the anticonvulsant Phenytoin. The Drug Safety Evaluation Division of the MFDS has prepared a change (proposal) in domestic drug permits based on the results of the EMA's review of drug safety information. The changes will be checked by the pharmaceutical industry and
- InterView
- “Roche reborn through customer-centric reorganization”
- by Eo, Yun-Ho Jun 21, 2022 05:54am
- Multinational pharmaceutical companies are known to endlessly pursue change. In addition to active acquisitions, mergers, and spin-offs, the companies boldly reduce and expand their many originations in line with the new drug development trend, and show no hesitation in consolidating or reorganizing departments. Their endless evolution for e
- Company
- Takeda Korea appoints Sun Jin Lee as head of Oncology BU
- by Jun 21, 2022 05:54am
- Takeda Pharmaceuticals Korea (General Manager HeeSeok Moon) announced on the 20th that it had promoted and appointed Manager Sun Jin (Justine) Lee as the Head of its Oncology BU. The new head, Lee, who joined Takeda Pharmaceuticals Korea as a marketing manager of the Hemophilia BU, developed creative marketing strategies and drew particip
- Company
- KIMS has signed a license agreement for Lipothasone
- by Nho, Byung Chul Jun 21, 2022 05:54am
- KIMS Pharmaceutical announced on the 20th that it has signed a contract with Japanese pharmaceutical company Mitsubishi Tanabe Pharma on the 17th to license Lipothasone. Through this contract, KIMS Pharmaceutical will officially release the product in August. According to KIMS Pharmaceutical, Lipothasone is the only Dexamethasone in Korea
- Policy
- The HIRA launched a benefit review for Tabrecta
- by Lee, Tak-Sun Jun 21, 2022 05:54am
- There are not many patients with MET mutation, but the prognosis is bad, so a treatment is urgently needed. It was found that the HIRA began a benefit review for targeted treatments for MET mutants, which appear in 3-4% of all non-small cell lung cancer patients. The MET mutation target anticancer drug landed in Korea in November last year
- Policy
- Drug price cut refund bill’s fate depends on LJC Chair
- by Lee, Jeong-Hwan Jun 20, 2022 06:04am
- Industry expectations are rising on the prospect that the constitution of the NA leadership in the second half of the year will directly affect the fate of the Bill to recover and retrieve drug price cuts. If the People Power Party, which had been criticizing the inadequacy of the bill, takes Chair of the Legislation and Judiciary committe
